Omeprazole

• UNSPSC Description:

  Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

• Target Antigen:

  Autophagy; Bacterial; Phospholipase; Proton Pump

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Autophagy;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Infection; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/Omeprazole.html

• Purity:

  99.74

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL

• Smiles:

  O=S(C1=NC2=CC=C(OC)C=C2N1)CC3=NC=C(C)C(OC)=C3C

• Molecular Weight:

  345.424

• References & Citations:

  [1]Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.|[2]Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37(1):145-50.|[3]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.Adv Sci (Weinh). 2023 Apr 24;e2207017.|Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X.|Nat Commun. 2023 Jul 14;14(1):4217.|Xenobiotica. 2024 Oct 24:1-29.|Chem Eng J. 2024 Dec 1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  73590-58-6